Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a
1+ 1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs …

Abstract Background As of June 2023, two pneumococcal conjugate vaccines, 20-(PCV20)
and 15-(PCV15) valent formulations, are recommended for US infants under a 3+ 1 …

Background The 15-valent pneumococcal conjugate vaccine (PCV15 or V114) has recently
been approved for pediatric vaccination against pneumococcal diseases (PDs) in Japan …

Objectives: Pneumococcal disease, caused by Streptococcus pneumoniae, is the leading
cause of mortality in children worldwide. The tremendous direct cost of hospital admissions …

Abstract Aim The US Food and Drug Administration approved the 20-valent pneumococcal
conjugate vaccine (PCV20) to prevent pneumococcal disease. In the context of routine …

This study aimed to evaluate the cost-effectiveness of routine childhood immunization with
the 20-valent pneumococcal conjugate vaccine (PCV20) in a four-dose regimen (3+ 1 …

Objectives The 13-valent pneumococcal conjugate vaccine (PCV13) has been
recommended for infants in Argentina's national immunization program (NIP) in a 2+ 1 …

Background Despite the demonstrated immunogenicity and safety of the 20-valent
pneumococcal conjugate vaccine (PCV20) in older adults, the cost-effectiveness of the …

Background Despite effective pneumococcal vaccines, pneumococcal disease (PD) exerts a
substantial burden on children. This study explored the clinical and economic burden of …